Microbiotica and Genentech have entered into a multi-year strategic collaboration to discover, develop, and commercialize biomarkers, targets and medicines for inflammatory bowel disease (IBD). Under the terms of the agreement, Microbiotica will utilize its precision metagenomics microbiome platform to analyze patient samples from clinical trials of Genentech’s investigational IBD medicines, in order to identify microbiome biomarker…